AGE-RELATED ANDROGEN DEFICIENCY. THE CURRENT STATE OF THE PROBLEM


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This paper reviews the modern concept of age-related androgen deficiency. The authors discuss the prevalence of androgen deficiency and its relationship with age, concomitant diseases, pharmacotherapy and other factors.

全文:

受限制的访问

作者简介

E. Finagina

Russian Medical Academy of Continuous Professional Education of Minzdrav of Russia

Email: lizafinagina@mail.ru
Ph.D. Student at the Department of Endoscopic Urology

O. Teodorovich

Russian Medical Academy of Continuous Professional Education of Minzdrav of Russia; Center of Urology, Research Clinical Center of JSC “RZD”

Dr.Med.Sci., Prof., Head of the Department of Endoscopic Urology

M. Shatokhin

Russian Medical Academy of Continuous Professional Education of Minzdrav of Russia; Center of Urology, Research Clinical Center of JSC “RZD”

Dr.Med.Sci., Professor at the Department ofEndoscopic Urology

S. Shekhovtsov

Center of Urology, Research Clinical Center of JSC “RZD”; N.I. Pirogov Russian National Research Medical University of Minzdrav of Russia

Dr.Med.Sci., Prof., Head of the Department of Urology, Andrology and Oncourology

M. Abdullaev

Russian Medical Academy of Continuous Professional Education of Minzdrav of Russia

Dr.Med.Sci., Professor at the Department of Endoscopic Urology

G. Borisenko

Russian Medical Academy of Continuous Professional Education of Minzdrav of Russia

Ph.D., Associate Professor at the Department of Endoscopic Urology

A. Krasnov

Center of Urology, Research Clinical Center of JSC “RZD”

Ph.D., Urologist

参考

  1. Araujo A.B., Esche G.R., Kupelian V. et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241-4247.
  2. Tajar A., Forti G., O'Neill, T.W. and EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Aging Study. J Clin Endocrinol Metab. 2010;95:1810-1818.
  3. Corona G., Maseroli E., Rastrelli G. et al. Characteristics of compensated hypogonadism in patients with sexual dysfunction. J Sex Med. 2014; 11: 1823-1834.
  4. Wang C., Nieschlag E., Swerdloff R., Behre H., Hellstrom W., Gooren L. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009;30: 1-9.
  5. Kato Y., Nomura A., Stemmermann Y.N. et al. Determinants of sex hormone levels in men as useful induces in hormone-related disorders. J. Clin. Epidemiol. 1992;45(12):1417-1421.
  6. Bhasin S. Approach to the patient Approach to the Infertile Man. J Clin Endocrinology Metabolism. 2007;92(7):1996-2004.
  7. Veldhuis J.D., Roemmich J.N., Richmond E.J., Bowers C.Y. Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition. Endocrine Rev. 2006;27(2):101-140.
  8. Oettel M. Naturwissenschaften. 2004;91:66.
  9. Wu F.C., Tajar A., Beynon J.M. and EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123-135.
  10. Maseroli E., Corona G., Rastrelli G. et al. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med. 2015; 12: 956-965.
  11. Corona G., Maggi M. Perspective: regulatory agencies’ changes to testosterone product labeling. J Sex Med. 2015;12:1690-1693.
  12. Nieschlag E., Lammers U., Freischem C.W., Langer K., Wickings E.J. Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab. 1982;55:676-668.
  13. Yeap B.B., Almeida O.P., Hyde Z. et al. Healthier lifestyle predicts higher circulating testosterone in older men: the Health In Men Study. Clin Endocrinol (Oxf). 2009; 70: 455-463.
  14. Sartorius G., Spasevska S., Idan A. et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol (Oxf). 2012; 77: 755-763.
  15. Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R., and Baltimore Longitudinal Study ofAging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001; 86: 724-731.
  16. Araujo A.B., O'Donnell A.B., Brambilla D.J. et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study.J Clin Endocrinol Metab. 2004;89:5920-5926.
  17. Wu F.C., Tajar A., Pye S.R. and European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008; 93: 2737-2745.
  18. Feldman H.A., Longcope C., Derby C.A. et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study.J Clin Endocrinol Metab. 2002; 87: 589-598.
  19. Laaksonen D.E., Niskanen L., Punnonen K. et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004; 27: 1036-1041.
  20. Laaksonen D.E., Niskanen L., Punnonen K. et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005; 90: 712-719.
  21. Allan C.A., McLachlan, R.I. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17: 224-232.
  22. MacDonald A.A., Herbison G.P., Showell M., Farquhar C.M. The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum Reprod Update. 2010; 16: 293-311.
  23. Brand J.S., van der Tweel I., Grobbee D.E., Emmelot-Vonk M.H., and van der Schouw Y.T. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol. 2011;40:189-207.
  24. Wang C., Jackson G., Jones, T.H. et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34:1669-1675.
  25. Novikova E.G., Selyatickaya V.G., Lutov, Yu.V., Mitrofanov I.M. The relationship of hypogonadism with metabolic syndrome in men of different age groups. Vestnik NGU. 2012; 10( 1):54-62.
  26. Ding E.L., Song Y., Malik V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006; 295: 1288-1299.
  27. Shores M.M., Matsumoto A.M., Sloan K.L., Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006; 166: 1660-1665.
  28. Corona G., Mannucci E., Schulman C. et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol. 2006;50:595-604.
  29. Corona G., Vignozzi L., Sforza A., Mannucci E., Maggi M. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418:120-133.
  30. Muller M., den Tonkelaar I., Thijssen J., Grobbee D., Van der Schouw Y. Endogenous sex hormones in men aged 40-80 years. Eur. J Endocrinol. 2003;149:583-589.
  31. Pecherskij A.V., Dombrovskaya Yu. A., Pecherskaya O.V. The role of partial age-related androgen deficiency in the development of insulin resistance and disorders of microcirculation. Materials of the International Congress on Andrology. Sochi, Dagomys, 2009. P. 132
  32. Vorslov L.O., Morgunov L. Yu. The relationship between a decrease in testosterone levels in men and a violation of lipid metabolism. Terapevt. 2007;12: 59-65
  33. Frolov D.S., Halimov Yu.S., Shustov S.B. Age-related androgen deficiency in men with ischemic heart disease. Problemy endokrinologii. 2011;57(2):19- 22
  34. Tyuzikov I.A., Grekov E.A., Kalinchenko S. Yu. Features of clinical course and morphometric parameters of benign prostatic hyperplasia in men with metabolic syndrome and androgen deficiency. Urologiia. 2015;(5): 66- 69
  35. Tyuzikov I.A., Martov А.Т., Kalinchenko S.Yu. Influence of obesity and androgen deficiency on prostatic blood circulation. Byulleten Sibirskoj mediciny. 2012;2:80-83.
  36. Mulligan T., Frick M.F., Zuraw Q.C., Stemhagen A., McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762-769.
  37. Bonin-Guillaume S., Herrmann F.R., Boillat D., Szanto I., Michel J.P., Rohner-Jeanrenaud F., Vischer U.M. de Carvalho, Colaco A.L. Fortes Z.B. Cytokines, endothelial dysfunction, and insulin resistance. Arq. Bras. Endocrinol. Metabol. 2006;2(50):304-312.
  38. Guzder R.N., Gatling W., Mullee M.A., Byrne C.D. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia. 2006;49(11):49-55.
  39. Ashby J., Goldmeier D., Sadeghi-Nejad H. Hypogonadism in human immunodeficiency virus-positive men. Korean J Urol. 2014;55:9-16.
  40. Wong N., Levy M., Stephenson I. Hypogonadism in the HIV-Infected Man. Curr Treat Options Infect Dis. 2017;9(1):104-116.
  41. Attal P., Chanson P. Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab. 2010;95:483-495.
  42. Gambineri A., Pelusi C., Pasquali R. Testosterone levels in obese male patients with obstructive sleep apnea syndrome: relation to oxygen desaturation, body weight, fat distribution and the metabolic parameters. J Endocrinol Invest. 2003; 26: 493-498.
  43. Luboshitzky R., Aviv A., Hefetz A. et al. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab. 2002; 87: 3394-3398.
  44. Singer F., Zumoff B. Subnormal serum testosterone levels in male internal medicine residents. Steroids. 1992;57:86-89.
  45. Nilsson P.M., Mqller L., Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. J Intern Med. 1995;237:479-486.
  46. Woolf P.D., Hamill R.W., McDonald J.V., Lee L.A., Kelly M. Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab. 1985; 60: 444-450.
  47. Thompson S.T. Prevention of male infertility. Urol Clin North Am. 1994;21:365-376.
  48. Rahnema C.D., Lipshultz L.I., Crosnoe L.E., Kovac J.R., Kim E.D. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101:1271-1279.
  49. Morrison D., Capewell S., Reynolds S., Thomas J., Ali N., Read G., et al. Testosterone levels during systemic and inhaled corticosteroid therapy. Respir Med. 1994;88:659-663.
  50. Birthi P., Nagar V.R., Nickerson R., Sloan, P.A. Hypogonadism associated with long-term opioid therapy: a systematic review. J Opioid Manag. 2015; 11: 255-278.
  51. Rajagopal A., Vassilopoulou-Sellin R., Palmer J., Kaur G., Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100:851-858.
  52. Katz N., Mazer N. The impact of opioids on the endocrine system. Clin J Pain. 2009;25:170-175.
  53. Schooling C.M., Au Yeung S.L., Freeman G., Cowling B.J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11:57.
  54. Rosen R., Kostis J., JekelisA. Beta-blocker effects on sexual function in normal males. Arch Sex Behav. 1988;17: 241-255.
  55. Howell S.J., Shalet S.M. Spermatogenesis after cancer treatment: damage and recovery.J Natl Cancer Inst Monogr. 2005;34:12-17.
  56. Thompson I., Goodman P., Tangen C., Lucia M., Miller G., Ford L. et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349: 215-224.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##